GIA
NKTR icon

Gateway Investment Advisers’s Nektar Therapeutics NKTR Stock Holding History

Gateway Investment Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-458
Closed -$244K – 633
2019
Q2 		$244K Hold
458
– – ﹤0.01% 647
2019
Q1 		$231K Hold
458
– – ﹤0.01% 645
2018
Q4 		$226K Buy
458
+1
+0.2% +$604 ﹤0.01% 652
2018
Q3 		$418K Sell
457
-9
-2% -$7.68K ﹤0.01% 599
2018
Q2 		$342K Sell
466
-48
-9% -$55.3K ﹤0.01% 622
2018
Q1 		$819K Buy
+514
New +$662K 0.01% 507

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gateway Investment Advisers's NKTR Position: Q3 2019 in Review

Gateway Investment Advisers sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 458 shares — an estimated $244K sold.

Gateway Investment Advisers first reported a position in NKTR in Q1 2018 and held it in 6 quarters. The position peaked at $819K in Q1 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Gateway Investment Advisers reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Gateway Investment Advisers sold 458 Nektar Therapeutics shares in Q3 2019, an estimated $244K.
  • Gateway Investment Advisers first reported a position in Nektar Therapeutics in Q1 2018 and held it in 6 quarters.
  • Gateway Investment Advisers's Nektar Therapeutics position peaked at $819K in Q1 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Gateway Investment Advisers's 13F filing for Q3 2019, filed 15 Oct 2019.